The good new is that you have a mutation that may respond to one of the recently approved PARP inhibitors. The somewhat bad news is that response with the ATM mutation is not nearly as strong or as long-lasting as response with the BRCA mutation. But better some than nothing, and it can vary - you may get lucky. The other somewhat bad news is that the PARP inhibitors may be toxic in some men. This explains more:
BTW, the two newly approved hormonal therapies, Erleada and Nubiqa, are said to slow down AR amplification (which always occurs). While you don't have the type of diagnosis for which they have been approved, my friend was able to get Nubiqa because he had a small stroke. It might be worth discussing with your oncologist to see if he can stretch your diagnosis a bit to get you one of them.
Tall Allen sums it up better than I can but any use of PARPs can have good or bad outcome.
Men who don't have high Ga68 avidity in PsMa scans will be told Lu177 won't work for them and if all known ADT and chemo has already failed and DNA analysis shows you might benefit with a PARP that suits your DNA profile, then I'd agree with docs wanting to give you Olaparib or whatever else because there may not be anything else you can try.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.